WO2006066965A3 - Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer - Google Patents
Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer Download PDFInfo
- Publication number
- WO2006066965A3 WO2006066965A3 PCT/EP2005/014021 EP2005014021W WO2006066965A3 WO 2006066965 A3 WO2006066965 A3 WO 2006066965A3 EP 2005014021 W EP2005014021 W EP 2005014021W WO 2006066965 A3 WO2006066965 A3 WO 2006066965A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prostate cancer
- value
- ratio
- psa
- amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
Abstract
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007547391A JP4944041B2 (en) | 2004-12-24 | 2005-12-23 | Urinary sediment and / or urine mRNA ratio that is a prognostic marker and / or a terranostic marker for prostate cancer |
EP05843726A EP1761651B1 (en) | 2004-12-24 | 2005-12-23 | Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
CA2594125A CA2594125C (en) | 2004-12-24 | 2005-12-23 | Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
DE602005019294T DE602005019294D1 (en) | 2004-12-24 | 2005-12-23 | MRNA RATIO IN HARMET DIMENTS AND / OR HARN AS PROGNOSTIC AND / OR THEROSTATIC MARKERS FOR PROSTATE CANCER |
AT05843726T ATE457362T1 (en) | 2004-12-24 | 2005-12-23 | MRNA RATIO IN URINE SEDIMENTS AND/OR URINE AS PROGNOSTIC AND/OR THERANOSTIC MARKERS FOR PROSTATE CANCER |
AU2005318369A AU2005318369B2 (en) | 2004-12-24 | 2005-12-23 | mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
DK05843726.0T DK1761651T3 (en) | 2004-12-24 | 2005-12-23 | MNRA ratios in urinary sediments and / or urine as a prognostic and / or teranostic marker for prostate cancer |
US11/794,048 US7960109B2 (en) | 2004-12-24 | 2005-12-23 | mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
IL183476A IL183476A0 (en) | 2004-12-24 | 2007-05-28 | Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
US13/101,440 US8257924B2 (en) | 2004-12-24 | 2011-05-05 | mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
US13/571,124 US20120309007A1 (en) | 2004-12-24 | 2012-08-09 | Prostate cancer prognostic compositions and kits |
US13/914,303 US9096907B2 (en) | 2004-12-24 | 2013-06-10 | Prostate cancer prognostic compositions and kits |
US14/745,955 US20150307948A1 (en) | 2004-12-24 | 2015-06-22 | Prostate cancer prognostic compositions and kits |
US15/097,758 US9951390B2 (en) | 2004-12-24 | 2016-04-13 | Prostate cancer prognostic compositions and kits |
US15/924,040 US10752957B2 (en) | 2004-12-24 | 2018-03-16 | Prostate cancer prognostic compositions and kits |
US17/001,352 US20200392588A1 (en) | 2004-12-24 | 2020-08-24 | Prostate Cancer Prognostic Compositions and Kits |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,491,067 | 2004-12-24 | ||
CA002491067A CA2491067A1 (en) | 2004-12-24 | 2004-12-24 | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
US71955705P | 2005-09-23 | 2005-09-23 | |
US60/719,557 | 2005-09-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/794,048 A-371-Of-International US7960109B2 (en) | 2004-12-24 | 2005-12-23 | mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
US13/101,440 Continuation US8257924B2 (en) | 2004-12-24 | 2011-05-05 | mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006066965A2 WO2006066965A2 (en) | 2006-06-29 |
WO2006066965A3 true WO2006066965A3 (en) | 2006-10-26 |
Family
ID=36636708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/014021 WO2006066965A2 (en) | 2004-12-24 | 2005-12-23 | Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
Country Status (13)
Country | Link |
---|---|
US (8) | US7960109B2 (en) |
EP (3) | EP2226394B1 (en) |
JP (1) | JP4944041B2 (en) |
AT (1) | ATE457362T1 (en) |
AU (1) | AU2005318369B2 (en) |
CA (2) | CA2491067A1 (en) |
DE (1) | DE602005019294D1 (en) |
DK (1) | DK1761651T3 (en) |
ES (2) | ES2546193T3 (en) |
HK (1) | HK1148315A1 (en) |
IL (1) | IL183476A0 (en) |
WO (1) | WO2006066965A2 (en) |
ZA (1) | ZA200703746B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US7008765B1 (en) * | 1997-04-10 | 2006-03-07 | The Johns Hopkins University | PCA3, PCA3 genes, and methods of use |
PT1222266E (en) | 1999-09-29 | 2006-07-31 | Diagnocure Inc | PCA3 MESSENGER RNA IN BENEFICIAL AND MALIGNAL PROSTATE TISSUES |
ES2427853T3 (en) | 2003-02-07 | 2013-11-04 | Diagnocure Inc. | Procedure to detect prostate cancer in a sample |
US11105808B2 (en) | 2004-11-12 | 2021-08-31 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
CA2491067A1 (en) * | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
JP2009531324A (en) | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Engineered anti-prostatic stem cell antigen (PSCA) antibody for cancer targeting |
JP4943074B2 (en) * | 2006-07-03 | 2012-05-30 | シスメックス株式会社 | Method and apparatus for determining cancer metastasis |
WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
WO2009085196A1 (en) * | 2007-12-21 | 2009-07-09 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
GB2465088C (en) * | 2008-10-30 | 2016-01-27 | Caris Mpi Inc | miRNA expression in the characterisation and classification of cancer |
JP2012507300A (en) * | 2008-10-30 | 2012-03-29 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Method for evaluating RNA patterns |
WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
WO2010096486A1 (en) | 2009-02-17 | 2010-08-26 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
JP2010233542A (en) * | 2009-03-31 | 2010-10-21 | Kanazawa Univ | Primer set and probe capable of distinguishing and amplifying two kinds of splicing variants of rage gene |
EP2320234A1 (en) | 2009-11-06 | 2011-05-11 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker combination for prostate cancer diagnosis |
EP2320235A1 (en) | 2009-11-06 | 2011-05-11 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker for prostate cancer diagnosis |
RU2673908C2 (en) | 2009-12-02 | 2018-12-03 | Имэджинэб, Инк. | J591 minibodies and cys-diabodies for targeted delivery of human prostate specific membrane antigen (psma) and methods for their use |
JP5808349B2 (en) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | Biomarkers for theranosis |
KR20130043104A (en) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | Circulating biomarkers for disease |
MX346671B (en) * | 2010-04-16 | 2017-03-29 | Hunter Douglas Inc * | A process and system for manufacturing a roller blind. |
WO2012031207A2 (en) | 2010-09-03 | 2012-03-08 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
ES2541054T3 (en) * | 2010-10-20 | 2015-07-15 | Université De Bordeaux | Signatures of the clinical outcome in gastrointestinal stromal tumors and method of treatment of gastrointestinal stromal tumors |
US9534256B2 (en) | 2011-01-06 | 2017-01-03 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer |
EP2574929A1 (en) | 2011-09-28 | 2013-04-03 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker in diagnosing prostate cancer (PC) |
JP2016526922A (en) * | 2013-08-06 | 2016-09-08 | エクソサム ダイアグノスティクス,インコーポレイティド | Urine biomarker cohort, gene expression characteristics, and methods of use thereof |
WO2015109234A1 (en) | 2014-01-16 | 2015-07-23 | Illumina, Inc. | Gene expression panel for prognosis of prostate cancer recurrence |
US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
US11137409B2 (en) | 2014-11-06 | 2021-10-05 | The Regents Of The University Of Colorado, A Body Corporate | Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent |
WO2016200765A1 (en) | 2015-06-08 | 2016-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Time independent viscoelastic analysis parameter for prediction of patient outcome |
AU2016304764C1 (en) | 2015-08-07 | 2023-06-01 | Imaginab, Inc. | Antigen binding constructs to target molecules |
WO2017091640A1 (en) | 2015-11-24 | 2017-06-01 | The Johns Hopkins University | Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo |
WO2017205074A1 (en) | 2016-05-11 | 2017-11-30 | Chapman Michael P | Viscoelastic analysis in patients with disease associated with the cardiovascular system |
US11913072B2 (en) * | 2016-05-13 | 2024-02-27 | Roche Molecular Systems, Inc. | Detection of MET exon 14 deletions and associated therapies |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
JP7044114B2 (en) * | 2017-11-13 | 2022-03-30 | 株式会社リコー | Device for detection judgment |
US11530451B2 (en) | 2018-03-02 | 2022-12-20 | The Johns Hopkins University | Methods for prostate cancer detection |
CN110423797A (en) * | 2019-07-11 | 2019-11-08 | 杨海涛 | A kind of primer, method and the kit of the dual real-time PCR of prostate cancer PCA3 gene |
CN114743593B (en) * | 2022-06-13 | 2023-02-24 | 北京橡鑫生物科技有限公司 | Construction method of prostate cancer early screening model based on urine, screening model and kit |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023550A2 (en) * | 1999-09-29 | 2001-04-05 | Diagnocure Inc. | Pca3 messenger rna species in benign and malignant prostate tissues |
WO2004070056A2 (en) * | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2422956A1 (en) * | 1978-04-13 | 1979-11-09 | Pasteur Institut | METHOD OF DETECTION AND CHARACTERIZATION OF A NUCLEIC ACID OR OF A SEQUENCE OF THE SAME, AND ENZYMATIC REAGENT FOR THE IMPLEMENTATION OF THIS PROCESS |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4690890A (en) | 1984-04-04 | 1987-09-01 | Cetus Corporation | Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay |
US4786600A (en) | 1984-05-25 | 1988-11-22 | The Trustees Of Columbia University In The City Of New York | Autocatalytic replication of recombinant RNA |
JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4851331A (en) * | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
FR2602592B1 (en) | 1986-08-06 | 1989-06-30 | Alain Baret | USE OF THE ENZYMATIC XANTHINE-OXYDASE SYSTEM IN IMMUNOALYSIS, CORRESPONDING ASSAY PROCESSES AND REAGENT PACKAGES NECESSARY FOR THE IMPLEMENTATION OF THESE PROCESSES. |
US5541308A (en) | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5149625A (en) * | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
US5639604A (en) | 1987-09-21 | 1997-06-17 | Gen-Probe Incorporated | Homogeneous protection assay |
US5585481A (en) * | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5283174A (en) | 1987-09-21 | 1994-02-01 | Gen-Probe, Incorporated | Homogenous protection assay |
AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
US5002867A (en) | 1988-04-25 | 1991-03-26 | Macevicz Stephen C | Nucleic acid sequence determination by multiple mixed oligonucleotide probes |
NL8801147A (en) | 1988-05-02 | 1989-12-01 | Tno | METHOD FOR DETECTING GENETIC VARIATION, AND SUITABLE KIT. |
DK167254B1 (en) | 1988-07-21 | 1993-09-27 | Hartmann As Brdr | PROCEDURE FOR THE PREPARATION OF FORMED ARTICLES OF A FLUIDIZED CELLULOSE FIBER MATERIAL |
US5183949A (en) * | 1988-09-22 | 1993-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids |
US5118801A (en) | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
US5219989A (en) | 1988-12-13 | 1993-06-15 | Mcgill University | Bifunctional protein for the isolation of capped mRNA |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5175383A (en) * | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
US5112736A (en) * | 1989-06-14 | 1992-05-12 | University Of Utah | Dna sequencing using fluorescence background electroblotting membrane |
US5656207A (en) * | 1989-06-24 | 1997-08-12 | Gen Probe Incorporated | Detecting or quantifying multiple analytes using labelling techniques |
US5174986A (en) * | 1989-07-05 | 1992-12-29 | Genpharm International, Inc. | Method for determining oncogenic potential of a chemical compound |
CA2020958C (en) * | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
IE911869A1 (en) | 1990-06-01 | 1991-12-04 | Regeneron Pharma | A family of map2 protein kinases |
AU662906B2 (en) | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
CA2082411A1 (en) * | 1991-06-28 | 1992-12-29 | Robert D. Rosenberg | Localized oligonucleotide therapy |
WO1993003743A1 (en) | 1991-08-16 | 1993-03-04 | The General Hospital Corporation | Method of gene delivery to post-mitotic cells |
WO1993008845A1 (en) | 1991-11-08 | 1993-05-13 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
CA2125947A1 (en) * | 1991-12-16 | 1993-06-24 | Fateme Sima Sariaslani | Constitutive expression of p450soy and ferredoxin-soy in streptomyces, and biotransformation of chemicals by recombinant organisms |
DK1695979T3 (en) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gapped modified oligonucleotides |
CA2135073C (en) * | 1992-05-06 | 2002-11-19 | Daniel L. Kacian | Nucleic acid sequence amplification method, composition and kit |
US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
EP1757694A3 (en) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US5503980A (en) * | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5773705A (en) * | 1992-12-31 | 1998-06-30 | Wisconsin Alumni Research Foundation | Ubiquitin fusion protein system for protein production in plants |
BR9405707A (en) | 1993-01-07 | 1996-08-06 | Univ Jefferson | Anti-sense inhibition of c-myc to modulate the proliferation of smooth muscle cells |
US5422252A (en) * | 1993-06-04 | 1995-06-06 | Becton, Dickinson And Company | Simultaneous amplification of multiple targets |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US5861242A (en) | 1993-06-25 | 1999-01-19 | Affymetrix, Inc. | Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same |
US6323184B1 (en) | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
US5925517A (en) * | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
CA2185239C (en) * | 1994-03-16 | 2002-12-17 | Nanibhushan Dattagupta | Isothermal strand displacement nucleic acid amplification |
AU2292495A (en) | 1994-04-15 | 1995-11-10 | Trustees Of Columbia University In The City Of New York, The | Method for molecular staging of prostate cancer |
JPH10500310A (en) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | PNA probes for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
WO1996011266A2 (en) | 1994-10-05 | 1996-04-18 | Amgen Inc. | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein |
EP0709466B1 (en) * | 1994-10-28 | 2006-09-27 | Gen-Probe Incorporated | Compositions and methods for the simultaneous detection and quantification of multiple specific nucleic acid sequences |
US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
DE19513152A1 (en) * | 1995-04-07 | 1996-10-10 | Bundesrep Deutschland | Use of an "immunodeficiency virus suppressing lymphokine (ISL)" to inhibit virus multiplication, in particular of retroviruses |
US5731148A (en) | 1995-06-07 | 1998-03-24 | Gen-Probe Incorporated | Adduct protection assay |
US6130038A (en) | 1996-07-16 | 2000-10-10 | Gen-Probe Incorporated | Method for amplifying target nucleic acids using modified primers |
US6479263B1 (en) | 1996-11-14 | 2002-11-12 | Baylor College Of Medicine | Method for detection of micrometastatic prostate cancer |
US6465611B1 (en) * | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
US6261562B1 (en) * | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
EP1005546A2 (en) * | 1997-02-25 | 2000-06-07 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
US6800746B2 (en) * | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6395278B1 (en) * | 1997-02-25 | 2002-05-28 | Corixa Corporation | Prostate specific fusion protein compositions |
US7008765B1 (en) * | 1997-04-10 | 2006-03-07 | The Johns Hopkins University | PCA3, PCA3 genes, and methods of use |
KR20010012175A (en) * | 1997-05-02 | 2001-02-15 | 다니엘 엘. 캐시앙, 헨리 엘. 노르호프, 피터 알. 쉬어리 | Two-step hybridization and capture of a polynucleotide |
US6534273B2 (en) * | 1997-05-02 | 2003-03-18 | Gen-Probe Incorporated | Two-step hybridization and capture of a polynucleotide |
JP4672820B2 (en) * | 1997-05-08 | 2011-04-20 | メルク シャープ エンド ドーム リミテッド | Substituted 1,2,4-triazolo [3,4-a] phthalazine derivatives as GABAα5 ligands |
ATE557103T1 (en) * | 1997-05-30 | 2012-05-15 | Trovagene Inc | METHOD FOR DETECTING NUCLEIC ACID SEQUENCES IN URINE |
US20020035244A1 (en) * | 1997-09-09 | 2002-03-21 | Maurice Cohen | Reagents and methods useful for detecting diseases of the prostate |
US6124120A (en) | 1997-10-08 | 2000-09-26 | Yale University | Multiple displacement amplification |
US6200765B1 (en) * | 1998-05-04 | 2001-03-13 | Pacific Northwest Cancer Foundation | Non-invasive methods to detect prostate cancer |
CN100419079C (en) | 1998-07-14 | 2008-09-17 | 科里克萨有限公司 | Compositions and methods for therapy and diagnosis of prostate cancer |
US6037130A (en) | 1998-07-28 | 2000-03-14 | The Public Health Institute Of The City Of New York, Inc. | Wavelength-shifting probes and primers and their use in assays and kits |
WO2000044940A2 (en) | 1999-01-28 | 2000-08-03 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
FI990382A0 (en) | 1999-02-23 | 1999-02-23 | Arctic Partners Oy Ab | New diagnostic method |
US6528260B1 (en) * | 1999-03-25 | 2003-03-04 | Genset, S.A. | Biallelic markers related to genes involved in drug metabolism |
CA2368385C (en) | 1999-03-26 | 2012-05-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Prostate-specific gene, pcgem1, and methods of using pcgem1 to detect, treat, and prevent prostate cancer |
WO2001025272A2 (en) | 1999-10-04 | 2001-04-12 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
AU7859900A (en) | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
AU1656501A (en) | 1999-11-12 | 2001-06-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP1238116B1 (en) | 1999-12-17 | 2008-04-16 | Bio Merieux | Process for labeling a nucleic acid |
CA2397741A1 (en) | 2000-01-14 | 2001-07-19 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
AU2001236519A1 (en) * | 2000-01-24 | 2001-07-31 | Millennium Pharmaceuitcals, Inc. | Identification, assessment, prevention, and therapy of prostate cancer |
AU2001241541A1 (en) | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
AU2001249549A1 (en) | 2000-03-27 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
FR2810114B1 (en) | 2000-06-13 | 2002-08-23 | Bio Merieux | METHOD, METHOD, IMMUNOLOGICAL TEST AND DIAGNOSTIC KIT FOR PROSTATE ADENOCARCINOMA OR BENIGN PROSTATE HYPERTROPHY |
US20030031678A1 (en) | 2000-09-19 | 2003-02-13 | Shujath Ali | Compositions and methods relating to prostate specific genes and proteins |
AU2002215345A1 (en) | 2000-10-13 | 2002-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer |
US6897024B2 (en) * | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
CA2432365A1 (en) * | 2003-06-30 | 2004-12-30 | Jack A. Schalken | Specific method of prostate cancer detection based on pca3, and kits therefore |
CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
-
2004
- 2004-12-24 CA CA002491067A patent/CA2491067A1/en not_active Abandoned
-
2005
- 2005-12-23 DK DK05843726.0T patent/DK1761651T3/en active
- 2005-12-23 EP EP10152258.9A patent/EP2226394B1/en active Active
- 2005-12-23 DE DE602005019294T patent/DE602005019294D1/en active Active
- 2005-12-23 WO PCT/EP2005/014021 patent/WO2006066965A2/en active Application Filing
- 2005-12-23 JP JP2007547391A patent/JP4944041B2/en active Active
- 2005-12-23 US US11/794,048 patent/US7960109B2/en active Active
- 2005-12-23 ES ES10152258.9T patent/ES2546193T3/en active Active
- 2005-12-23 AT AT05843726T patent/ATE457362T1/en active
- 2005-12-23 ES ES05843726T patent/ES2340513T3/en active Active
- 2005-12-23 AU AU2005318369A patent/AU2005318369B2/en active Active
- 2005-12-23 EP EP10181472A patent/EP2325334A1/en not_active Withdrawn
- 2005-12-23 CA CA2594125A patent/CA2594125C/en active Active
- 2005-12-23 EP EP05843726A patent/EP1761651B1/en active Active
-
2007
- 2007-05-09 ZA ZA200703746A patent/ZA200703746B/en unknown
- 2007-05-28 IL IL183476A patent/IL183476A0/en unknown
-
2011
- 2011-03-07 HK HK11102244.7A patent/HK1148315A1/en unknown
- 2011-05-05 US US13/101,440 patent/US8257924B2/en active Active
-
2012
- 2012-08-09 US US13/571,124 patent/US20120309007A1/en not_active Abandoned
-
2013
- 2013-06-10 US US13/914,303 patent/US9096907B2/en active Active
-
2015
- 2015-06-22 US US14/745,955 patent/US20150307948A1/en not_active Abandoned
-
2016
- 2016-04-13 US US15/097,758 patent/US9951390B2/en active Active
-
2018
- 2018-03-16 US US15/924,040 patent/US10752957B2/en active Active
-
2020
- 2020-08-24 US US17/001,352 patent/US20200392588A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001023550A2 (en) * | 1999-09-29 | 2001-04-05 | Diagnocure Inc. | Pca3 messenger rna species in benign and malignant prostate tissues |
WO2004070056A2 (en) * | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
Non-Patent Citations (9)
Title |
---|
DATABASE EMBL [online] 31 August 2004 (2004-08-31), "Sequence 10 from Patent WO2004070056.", retrieved from EBI accession no. EM_PAT:CQ855954 Database accession no. CQ855954 * |
DATABASE EMBL [online] 31 August 2004 (2004-08-31), "Sequence 11 from Patent WO2004070056.", retrieved from EBI accession no. EM_PAT:CQ855955 Database accession no. CQ855955 * |
DATABASE EMBL [online] 31 August 2004 (2004-08-31), "Sequence 9 from Patent WO2004070056.", retrieved from EBI accession no. EM_PAT:CQ855953 Database accession no. CQ855953 * |
DE KOK JACQUES B ET AL: "DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.", CANCER RESEARCH. 1 MAY 2002, vol. 62, no. 9, 1 May 2002 (2002-05-01), pages 2695 - 2698, XP002391713, ISSN: 0008-5472 * |
GANDINI O ET AL: "IS DD3 A NEW PROSTATE-SPECIFIC GENE?", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 23, no. 1A, January 2003 (2003-01-01), pages 305 - 308, XP009032063, ISSN: 0250-7005 * |
HESSELS D ET AL: "DD3PCA3-BASED MOLECULAR URINE ANALYSIS FOR THE DIAGNOSIS OF PROSTATE CANCER", EUROPEAN UROLOGY, S. KARGER AG., BASEL, CH, vol. 44, no. 1, July 2003 (2003-07-01), pages 8 - 16, XP009032062, ISSN: 0302-2838 * |
HORNINGER WOLFGANG ET AL: "Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.", UROLOGY. OCT 2002, vol. 60, no. 4 Suppl 1, October 2002 (2002-10-01), pages 31 - 35, XP002391714, ISSN: 1527-9995 * |
PARTIN ET AL: "Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 170, no. 5, November 2003 (2003-11-01), pages 1787 - 1791, XP005369901, ISSN: 0022-5347 * |
TINZL MARTINA ET AL: "DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer.", EUROPEAN UROLOGY. AUG 2004, vol. 46, no. 2, August 2004 (2004-08-01), pages 182 - 186 ; dis, XP002391712, ISSN: 0302-2838 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006066965A3 (en) | Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer | |
AU2010217160B2 (en) | Method for detecting metastasis of GI cancer | |
Yang et al. | Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis: HMGA2 as a prognostic marker of bladder cancer | |
Fritzsche et al. | ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer | |
WO2006113747A3 (en) | Diagnostic markers of breast cancer treatment and progression and methods of use thereof | |
EP2762574A1 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
JP2008524998A5 (en) | ||
WO2004076679A3 (en) | Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer | |
WO2007056192A3 (en) | Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers | |
WO2006036788A3 (en) | Methods and compositions for evaluating breast cancer prognosis | |
WO2002061128A3 (en) | Method of determining a chemotherapeutic regimen based on ercc1 expression | |
WO2007048076A3 (en) | Method for the diagnosis and prognosis of cancer | |
WO2006034456A3 (en) | Compositions and methods for detecting and treating tumors | |
WO2006092729A3 (en) | Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals | |
WO2011154698A8 (en) | Method,array and use thereof | |
WO2008116178A8 (en) | Systems and methods for diagnosis and prognosis of colorectal cancer | |
WO2008001357A3 (en) | Methods and kits for diagnosing cancer | |
Miyake et al. | Significance of micrometastases in pelvic lymph nodes detected by real‐time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy | |
WO2006091949A3 (en) | Phosphorylated p68 rna helicase as a marker for cancer and cancer metastasis | |
WO2006026714A8 (en) | Diagnosis and prognosis of cancer based on telomere length as measured on cytological specimens | |
WO2005113835A3 (en) | Kits and methods for indentification, assessment, prevention and therapy of breast cancer | |
Maane et al. | Evaluation of combined quantification of PCA3 and AMACR gene expression for molecular diagnosis of prostate cancer in Moroccan patients by RT-qPCR | |
Luscombe et al. | Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer | |
WO2002092767A3 (en) | DETECTION OF GD2 SYNTHASE mRNA AND USES THEREOF | |
WO2008086502A3 (en) | Molecular marker for clear renal cell carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005843726 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005843726 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/03746 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005318369 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 183476 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2005318369 Country of ref document: AU Date of ref document: 20051223 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007547391 Country of ref document: JP Ref document number: 2594125 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11794048 Country of ref document: US |